PAX5–PML acts as a dual dominant-negative form of both PAX5 and PML

PML/RARA Oxidation and Arsenic Binding Initiate the Antileukemia Response of As2O3

(2010) Marion Jeanne et al.   CANCER CELL

Arsenic Trioxide Controls the Fate of the PML-RAR  Oncoprotein by Directly Binding PML

(2010) X. W. Zhang et al.   SCIENCE

PAX5 mutations occur frequently in adult B-cell progenitor acute lymphoblastic leukemia and PAX5 haploinsufficiency is associated with BCR-ABL1 and TCF3-PBX1 fusion genes: a GRAALL study

(2009) J Familiades et al.   LEUKEMIA

PAX5/TEL Acts as a Transcriptional Repressor Causing Down-modulation of CD19, Enhances Migration to CXCL12, and Confers Survival Advantage in pre-BI Cells

(2008) G. Fazio et al.   CANCER RESEARCH

Acetylation of PML Is Involved in Histone Deacetylase Inhibitor-mediated Apoptosis

(2008) Fumihiko Hayakawa et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Incidence and diversity of PAX5 fusion genes in childhood acute lymphoblastic leukemia

(2008) K Nebral et al.   LEUKEMIA

Cloning of genes involved in chromosomal translocations by high-resolution single nucleotide polymorphism genomic microarray

(2008) N. Kawamata et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA